Mirabegron Dosing Recommendation
Mirabegron should be taken once daily, and the specific time of day does not matter for most patients, though nighttime dosing may provide additional benefit for those with prominent nocturia or morning urgency symptoms. 1
Dosing Frequency
The FDA-approved dosing for mirabegron extended-release tablets is once daily only 1. There is no twice-daily regimen for this medication. The standard approach is:
- Starting dose: 25 mg orally once daily
- Maximum dose: 50 mg orally once daily (can increase after 4-8 weeks if needed)
This once-daily dosing applies to both adult patients with overactive bladder and pediatric patients (≥3 years, ≥35 kg) with neurogenic detrusor overactivity 1.
Optimal Time of Day
For Most Patients: Either Morning or Evening
The FDA labeling does not specify a particular time of day for administration 1, and the drug can be taken at any consistent time. The extended-release formulation maintains therapeutic levels throughout the 24-hour period.
For Patients with Specific Symptom Patterns: Consider Nighttime Dosing
If your patient has prominent nocturia or morning urgency, nighttime dosing appears superior. A 2025 randomized controlled trial directly compared nighttime versus daytime dosing and found 2:
- Nocturia improvement: Nighttime dosing significantly reduced nocturia episodes at 4 weeks (5.65 ± 3.71 at baseline to 4.26 ± 2.60, p=0.019), while daytime dosing did not
- Morning urgency benefit: Nighttime dosing produced greater reductions in urgency episodes during 06:00-12:00 hours (change: -2.1 ± 3.7 vs 0.1 ± 2.4, p=0.003)
- All-day urgency: Nighttime dosing showed superior improvement in total daily urgency episodes (change: -6.4 ± 10.8 vs 0.1 ± 8.5, p=0.005)
For Patients with Emotional Dysfunction: Consider Daytime Dosing
Interestingly, the same trial found that daytime dosing provided better improvement in emotional quality of life measures (change: -17 ± 25 vs -6 ± 19, p=0.006) 2. If your patient has significant emotional distress related to OAB, morning dosing may be preferable.
Dose Adjustments for Special Populations
Renal Impairment
- eGFR 30-89: Start 25 mg, can increase to 50 mg once daily
- eGFR 15-29: 25 mg once daily maximum
- eGFR <15 or dialysis: Not recommended 1
Hepatic Impairment
- Child-Pugh A (mild): Start 25 mg, can increase to 50 mg once daily
- Child-Pugh B (moderate): 25 mg once daily maximum
- Child-Pugh C (severe): Not recommended 1
Clinical Pearls
The 50 mg dose is more effective than 25 mg. Meta-analysis data demonstrates that 50 mg once daily provides optimal efficacy with acceptable tolerability, showing approximately 13 ml more volume voided per micturition, five fewer micturitions, and four fewer incontinence episodes per week compared to placebo 3.
Long-term use is both safe and effective. Studies extending to 12 months show sustained benefit without increased adverse events 3, 4. The most common side effects (hypertension, UTI, headache, nasopharyngitis) occur at similar rates to placebo, with dry mouth reported in only 0.5-2.1% of patients 5.
Common Pitfalls to Avoid
- Do not prescribe twice-daily dosing - this is not an approved regimen and the extended-release formulation is designed for once-daily use only
- Do not use in uncontrolled hypertension - while safe in well-controlled hypertension 6, monitor blood pressure in all patients
- Do not confuse extended-release tablets with granules - these are different formulations and not interchangeable on a mg-per-mg basis 1